• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

    11/12/24 1:00:00 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email

    HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

    Event: Q4 Investor Summit
    Presentation Time: 9:00am - 9:30am ET
    Location: https://www.webcaster4.com/Webcast/Page/3075/51643

    • The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.

    • Take a deep dive with the best Investors in MicroCap

    • Live Q & A

    • Complimentary to Qualified Investors. Please REGISTER HERE.

    About the Investor Summit

    The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.

    Contact:
    Fred Rockwell
    [email protected]
    Investor Summit Group

    SOURCE: Pluri Inc.



    View the original press release on accesswire.com

    Get the next $PLUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care
    • Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

      Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025In addition to MAIT cells, Pluri's platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell ther

      4/10/25 8:30:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:19 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:22 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Zalts Liat was granted 67,857 shares, increasing direct ownership by 319% to 89,107 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:17 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

      Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

      11/11/24 6:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

      HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

      3/6/24 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

      HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

      7/13/23 2:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pluri Inc.

      10-Q - Pluri Inc. (0001158780) (Filer)

      5/13/25 4:03:23 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      5/8/25 8:30:07 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Shareholder Director Nominations

      8-K - Pluri Inc. (0001158780) (Filer)

      4/29/25 4:00:31 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/13/24 4:34:49 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/1/24 4:02:29 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      9/15/23 4:00:03 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care